ImmunoPrecise Antibodies Ltd. (IPA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
IPA currently has 46.2M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 71.29% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 29, 2025 |
20-F filing | 46.2M shares outstanding |
46M | 0 |
| Aug 06, 2024 |
F-3 filing: This F-3 filing relates to the registration of Common Shares and Note Shares for potential sale by the Selling Shareholder. |
27M | 0 |
| Jul 29, 2024 |
20-F filing | 26.9M shares outstanding |
27M | 0 |
| Jul 11, 2023 |
F-3 filing: The filing is an F-3 form, indicating a shelf registration for various types of securities including common shares, preferred shares, debt securities, warrants, units and subscription receipts. The specific terms will be detailed in a prospectus supplement. |
25M | 0 |
| Jul 10, 2023 |
40-F filing | 25.1M shares outstanding |
25M | 0 |
| Jul 29, 2022 |
40-F filing | 24.5M shares outstanding |
24M | 0 |
| Nov 09, 2020 |
F-10 filing: This is an F-10 filing outlining the terms for potential future offerings of various securities, including common shares, preferred shares, debt securities, warrants, units, and subscription receipts, with specific details to be provided in subsequent prospectus supplements. |
N/A | 0 |